WO2007075672A2 - Marqueurs pour le pronostic du cancer - Google Patents

Marqueurs pour le pronostic du cancer Download PDF

Info

Publication number
WO2007075672A2
WO2007075672A2 PCT/US2006/048411 US2006048411W WO2007075672A2 WO 2007075672 A2 WO2007075672 A2 WO 2007075672A2 US 2006048411 W US2006048411 W US 2006048411W WO 2007075672 A2 WO2007075672 A2 WO 2007075672A2
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
expression
patient
biological sample
antibody
Prior art date
Application number
PCT/US2006/048411
Other languages
English (en)
Other versions
WO2007075672A3 (fr
Inventor
U. Margaretha Wallon
George C. Prendergast
Karen A. Knudsen
Original Assignee
Lankenau Institute For Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lankenau Institute For Medical Research filed Critical Lankenau Institute For Medical Research
Publication of WO2007075672A2 publication Critical patent/WO2007075672A2/fr
Publication of WO2007075672A3 publication Critical patent/WO2007075672A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Abstract

La présente invention concerne des procédés, des kits et des compositions permettant de diagnostiquer, d'évaluer le pronostic ou de surveiller la progression d'un cancer chez un sujet, en particulier d'un cancer du sein.
PCT/US2006/048411 2005-12-23 2006-12-20 Marqueurs pour le pronostic du cancer WO2007075672A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75361905P 2005-12-23 2005-12-23
US60/753,619 2005-12-23

Publications (2)

Publication Number Publication Date
WO2007075672A2 true WO2007075672A2 (fr) 2007-07-05
WO2007075672A3 WO2007075672A3 (fr) 2008-06-26

Family

ID=38218531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/048411 WO2007075672A2 (fr) 2005-12-23 2006-12-20 Marqueurs pour le pronostic du cancer

Country Status (1)

Country Link
WO (1) WO2007075672A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010001585A1 (fr) 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anticorps anti-cdh3 marqués par un marqueur radioisotopique, et leurs utilisations
CN103562723A (zh) * 2011-03-27 2014-02-05 欧恩克斯特姆诊断学（毛里求斯）私人有限公司 用于识别肿瘤细胞的标记、方法及其试剂盒
EP2765140A3 (fr) * 2012-12-13 2015-06-03 Oxford Bio Therapeutics Limited Molécules de liaison mucin-13 ou cadherin-2 ou pour le traitement du cancer
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
US10005836B2 (en) 2014-11-14 2018-06-26 Novartis Ag Antibody drug conjugates
US10260104B2 (en) 2010-07-27 2019-04-16 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723581A (en) * 1995-05-05 1998-03-03 The Wistar Institute Of Anatomy And Biology Murine and human box-dependent myc-interacting protein (Bin1)
US5895748A (en) * 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
WO2002008765A2 (fr) * 2000-07-26 2002-01-31 Stanford University Marqueurs basocellulaires du cancer du sein et leurs utilisations
WO2002097395A2 (fr) * 2001-05-31 2002-12-05 Chiron Corporation Utilisation de p-cadherine comme cible dans la therapie anticancereuse
US20030166021A1 (en) * 1997-06-06 2003-09-04 The Wistar Institute Of Anatomy And Biology Box-dependent Myc-interacting protein (BIN1) compositions and uses therefor
US20040121343A1 (en) * 2002-12-24 2004-06-24 Biosite Incorporated Markers for differential diagnosis and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723581A (en) * 1995-05-05 1998-03-03 The Wistar Institute Of Anatomy And Biology Murine and human box-dependent myc-interacting protein (Bin1)
US5895748A (en) * 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
US20030166021A1 (en) * 1997-06-06 2003-09-04 The Wistar Institute Of Anatomy And Biology Box-dependent Myc-interacting protein (BIN1) compositions and uses therefor
WO2002008765A2 (fr) * 2000-07-26 2002-01-31 Stanford University Marqueurs basocellulaires du cancer du sein et leurs utilisations
US20030086934A1 (en) * 2000-07-26 2003-05-08 David Botstein Basal cell markers in breast cancer and uses thereof
WO2002097395A2 (fr) * 2001-05-31 2002-12-05 Chiron Corporation Utilisation de p-cadherine comme cible dans la therapie anticancereuse
US20040121343A1 (en) * 2002-12-24 2004-06-24 Biosite Incorporated Markers for differential diagnosis and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG M. ET AL.: 'Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4' ONCOGENE vol. 14, 1997, pages 2767 - 2774 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010001585A1 (fr) 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anticorps anti-cdh3 marqués par un marqueur radioisotopique, et leurs utilisations
EP2313504A1 (fr) * 2008-06-30 2011-04-27 Oncotherapy Science, Inc. Anticorps anti-cdh3 marqués par un marqueur radioisotopique, et leurs utilisations
JP2011526583A (ja) * 2008-06-30 2011-10-13 オンコセラピー・サイエンス株式会社 放射性同位体標識で標識された抗ｃｄｈ３抗体およびその使用
EP2313504A4 (fr) * 2008-06-30 2013-01-23 Oncotherapy Science Inc Anticorps anti-cdh3 marqués par un marqueur radioisotopique, et leurs utilisations
US8435749B2 (en) 2008-06-30 2013-05-07 Oncotherapy Science, Inc. Anti-CDH3 antibodies labeled with radioisotope label and uses thereof
US10260104B2 (en) 2010-07-27 2019-04-16 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
EP2691776A1 (fr) * 2011-03-27 2014-02-05 Oncostem Diagnostics (Mauritius) Pvt. Ltd. Marqueurs pour l'identification de cellules tumorales, procédés et trousse correspondants
EP2691776A4 (fr) * 2011-03-27 2015-04-15 Oncostem Diagnostics Mauritius Pvt Ltd Marqueurs pour l'identification de cellules tumorales, procédés et trousse correspondants
CN103562723A (zh) * 2011-03-27 2014-02-05 欧恩克斯特姆诊断学（毛里求斯）私人有限公司 用于识别肿瘤细胞的标记、方法及其试剂盒
EP2765140A3 (fr) * 2012-12-13 2015-06-03 Oxford Bio Therapeutics Limited Molécules de liaison mucin-13 ou cadherin-2 ou pour le traitement du cancer
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
US10005836B2 (en) 2014-11-14 2018-06-26 Novartis Ag Antibody drug conjugates
US10626172B2 (en) 2014-11-14 2020-04-21 Novartis Ag Antibody drug conjugates

Also Published As

Publication number Publication date
WO2007075672A3 (fr) 2008-06-26

Similar Documents

Publication Publication Date Title
EP2848700B1 (fr) Marqueurs pour le cancer de l'endomètre
US20220251662A1 (en) Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors
JPH10503087A (ja) 肺癌マーカー
WO2007075672A2 (fr) Marqueurs pour le pronostic du cancer
Pyle-Chenault et al. VSGP/F-spondin: a new ovarian cancer marker
EP1270745A2 (fr) Thymosin B15 comme marqueur dans le diagnostic et prognostic de cancer
US8747867B2 (en) Cancer markers
CN112626207B (zh) 一种用于区分非侵袭性和侵袭性无功能垂体腺瘤的基因组合
WO2006014903A2 (fr) Compositions et techniques d'utilisation d'antagonistes adam12 dans le traitement de maladie
AU2013332512B2 (en) SHON as a prognostic biomarker for cancer and as a predictor of response to endocrine therapy
US20090202474A1 (en) Expression of orphan gpr64 in inflammatory diseases
CA3082650A1 (fr) Nouveau variant de cip2a et ses utilisations
WO2008031165A1 (fr) Procédés et compositions pour le diagnostic et le traitement de tumeurs
KR102055350B1 (ko) 대장암의 항암제 내성 진단용 바이오마커 및 이의 용도
KR102028703B1 (ko) 유방암의 진단 및 치료를 위한 바이오 마커
US20100028867A1 (en) LRRTM1 Compositions and Methods of Their Use for the Diagnosis and Treatment of Cancer
KR102326119B1 (ko) 암의 면역 치료 후 예후 예측용 바이오 마커
JP2007510424A (ja) 分子マーカー
KR20220138789A (ko) 암 환자에 대하여 자연살해세포를 이용한 면역 항암 치료의 치료 반응성을 예측하는 방법
KR20210092355A (ko) 암의 진단용 조성물
JP2007503826A (ja) 乳癌のリスクの診断

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06848889

Country of ref document: EP

Kind code of ref document: A2